203 related articles for article (PubMed ID: 32440478)
1. Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9-Mediated Knockin of Retinoschisin 1 Gene-A Potential Nonviral Therapeutic Solution for X-Linked Juvenile Retinoschisis.
Chou SJ; Yang P; Ban Q; Yang YP; Wang ML; Chien CS; Chen SJ; Sun N; Zhu Y; Liu H; Hui W; Lin TC; Wang F; Zhang RY; Nguyen VQ; Liu W; Chen M; Jonas SJ; Weiss PS; Tseng HR; Chiou SH
Adv Sci (Weinh); 2020 May; 7(10):1903432. PubMed ID: 32440478
[TBL] [Abstract][Full Text] [Related]
2. Supramolecular nanosubstrate-mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies.
Yang P; Chou SJ; Li J; Hui W; Liu W; Sun N; Zhang RY; Zhu Y; Tsai ML; Lai HI; Smalley M; Zhang X; Chen J; Romero Z; Liu D; Ke Z; Zou C; Lee CF; Jonas SJ; Ban Q; Weiss PS; Kohn DB; Chen K; Chiou SH; Tseng HR
Sci Adv; 2020 Oct; 6(43):. PubMed ID: 33097539
[TBL] [Abstract][Full Text] [Related]
3. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
4. Supramolecular Nanosubstrate-Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion.
Ban Q; Yang P; Chou SJ; Qiao L; Xia H; Xue J; Wang F; Xu X; Sun N; Zhang RY; Zhang C; Lee A; Liu W; Lin TY; Ko YL; Antovski P; Zhang X; Chiou SH; Lee CF; Hui W; Liu D; Jonas SJ; Weiss PS; Tseng HR
Small; 2021 Jul; 17(28):e2100546. PubMed ID: 34105245
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticle-based vectors intended for the treatment of X-linked juvenile retinoschisis by gene therapy: In vivo approaches in Rs1h-deficient mouse model.
Apaolaza PS; Del Pozo-Rodríguez A; Torrecilla J; Rodríguez-Gascón A; Rodríguez JM; Friedrich U; Weber BH; Solinís MA
J Control Release; 2015 Nov; 217():273-83. PubMed ID: 26400864
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
8. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
9. Genetic Rescue of X-Linked Retinoschisis Mouse (
Vijayasarathy C; Zeng Y; Brooks MJ; Fariss RN; Sieving PA
Hum Gene Ther; 2021 Jul; 32(13-14):667-681. PubMed ID: 33019822
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
11. Generation of eGFP and Cre knockin rats by CRISPR/Cas9.
Ma Y; Ma J; Zhang X; Chen W; Yu L; Lu Y; Bai L; Shen B; Huang X; Zhang L
FEBS J; 2014 Sep; 281(17):3779-90. PubMed ID: 25039742
[TBL] [Abstract][Full Text] [Related]
12. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani.
Zhang WW; Matlashewski G
mBio; 2015 Jul; 6(4):e00861. PubMed ID: 26199327
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (
Shen Y; Cohen JL; Nicoloro SM; Kelly M; Yenilmez B; Henriques F; Tsagkaraki E; Edwards YJK; Hu X; Friedline RH; Kim JK; Czech MP
J Biol Chem; 2018 Nov; 293(44):17291-17305. PubMed ID: 30190322
[TBL] [Abstract][Full Text] [Related]
15. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
16. Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier.
Wang P; Zhang L; Xie Y; Wang N; Tang R; Zheng W; Jiang X
Adv Sci (Weinh); 2017 Nov; 4(11):1700175. PubMed ID: 29201613
[TBL] [Abstract][Full Text] [Related]
17. Morphological and Molecular Defects in Human Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis.
Huang KC; Wang ML; Chen SJ; Kuo JC; Wang WJ; Nhi Nguyen PN; Wahlin KJ; Lu JF; Tran AA; Shi M; Chien Y; Yarmishyn AA; Tsai PH; Yang TC; Jane WN; Chang CC; Peng CH; Schlaeger TM; Chiou SH
Stem Cell Reports; 2019 Nov; 13(5):906-923. PubMed ID: 31668851
[TBL] [Abstract][Full Text] [Related]
18. An ex vivo gene therapy approach in X-linked retinoschisis.
Bashar AE; Metcalfe AL; Viringipurampeer IA; Yanai A; Gregory-Evans CY; Gregory-Evans K
Mol Vis; 2016; 22():718-33. PubMed ID: 27390514
[TBL] [Abstract][Full Text] [Related]
19. Of men and mice: Human X-linked retinoschisis and fidelity in mouse modeling.
Vijayasarathy C; Sardar Pasha SPB; Sieving PA
Prog Retin Eye Res; 2022 Mar; 87():100999. PubMed ID: 34390869
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Dose-Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function.
Bush RA; Zeng Y; Colosi P; Kjellstrom S; Hiriyanna S; Vijayasarathy C; Santos M; Li J; Wu Z; Sieving PA
Hum Gene Ther; 2016 May; 27(5):376-89. PubMed ID: 27036983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
